RESUMO
PURPOSE: Dermatologic events (DEs) in patients with cancer treated with lapatinib, a small-molecule dual tyrosine kinase inhibitor (TKI) of epidermal growth factor receptor (EGFR [ErbB1]) and HER2 (ErbB2), were characterized. PATIENTS AND METHODS: Nine clinical trials of metastatic cancer were included in this analysis. Lapatinib was administered at doses ranging from 1000 to 1500 mg/day as monotherapy (n=928) or in combination with paclitaxel or capecitabine (n=491). Patients not treated with lapatinib comprised the control group. Dermatologic events included hand-foot syndrome, rash, hair disorder, dry skin, pruritus/urticaria, skin disorder, skin infection, and nail disorder; DEs were characterized based on type, time to onset, severity, duration, and required interventions. RESULTS: Fifty-eight percent of patients treated with lapatinib monotherapy, 74% treated with lapatinib plus paclitaxel or capecitabine, and 53% in the control group developed DEs. Among patients receiving lapatinib monotherapy, 55% experienced grade 1/2 DEs, 3% had grade 3 DEs, and no grade 4 DEs were observed. The most common DE was rash (43%); all other events occurred in Assuntos
Neoplasias/tratamento farmacológico
, Quinazolinas/administração & dosagem
, Quinazolinas/efeitos adversos
, Dermatopatias/etiologia
, Adulto
, Idoso
, Idoso de 80 Anos ou mais
, Protocolos de Quimioterapia Combinada Antineoplásica/administração & dosagem
, Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos
, Capecitabina
, Ensaios Clínicos como Assunto
, Desoxicitidina/administração & dosagem
, Desoxicitidina/análogos & derivados
, Relação Dose-Resposta a Droga
, Receptores ErbB/metabolismo
, Exantema/etiologia
, Feminino
, Fluoruracila/administração & dosagem
, Fluoruracila/análogos & derivados
, Humanos
, Lapatinib
, Masculino
, Pessoa de Meia-Idade
, Neoplasias/complicações
, Paclitaxel/administração & dosagem
, Resultado do Tratamento